Abbvie Inc
NYSE: ABBV
$214.47
+$2.70 (+1.3%)
Closing Price on March 17, 2025
ABBV Articles
In a new research note, Jefferies makes the case that earnings could give a lift to the sagging market, and with low expectations, the lift could be solid.
Published:
Last Updated:
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
Published:
Last Updated:
24/7 Wall St. screened the Jefferies Franchise Picks list for the top-yielding stocks and found four with outstanding growth potential.
Published:
Last Updated:
The November 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was up.
Published:
Last Updated:
Brokerage firm Jefferies has released its top pharmaceutical picks for the coming year and what to expect.
Published:
Last Updated:
The Franchise Picks list makes sense for solid growth investors looking for total return. Many of the stocks pay good dividends and have upside price potential.
Published:
Last Updated:
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, CDW, CSC, Eli Lilly, Ericsson, Gold Fields, JD.com, Nokia and Rackspace.
Published:
Last Updated:
Buying high-yielding blue chips for 2016 makes good sense. The Federal Reserve interest rate increases over the next two years are expected to remain very small and very measured.
Published:
Last Updated:
You may want to avoid these stocks over the next few months.
Published:
Last Updated:
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Published:
Last Updated:
The short interest data have been released for the October 30 settlement date, and for most of the selected pharmaceutical stocks, short interest was down.
Published:
Last Updated:
Buying stocks such as these, with solid growth potential and paying dividends higher than the 10-year Treasury debt, makes good sense now.
Published:
Last Updated:
Tuesday's top analyst upgrades, downgrades and initiations include AbbVie, Apple, Autodesk, JD.com, CyberArk, Dean Foods and Walt Disney.
Published:
Last Updated:
AbbVie reported better-than-expected third-quarter financial results before the markets opened on Friday.
Published:
Last Updated:
AbbVie is expected to report its third-quarter financial results before the markets open on Friday.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.